INFORMATION DISCLOSURE STATEMENT BY APPLICATION (Not for submission under 37 CFR 1.99) (Use several sheets if necessary)	Application Number:	10/716,141
	Filing Date:	November 18, 2003
	First Named Inventor:	Matthias ECKHARDT, et al.
	Art Unit:	1624
	Examiner Name:	Mark L. Berch
Comparable to PTO/SB/08a (05-07)	Attorney Docket Number:	01/1419

U.S. PATENTS

Examiner Initial*	Cite No.	Patent Number	Kind Code	Issue Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
	1.	2928833		1960-03-15	Leake et al	
	2.	4005208		1977-01-25	Bender	
	3.	4599338		1986-07-08	Regnier et al.	*This patent appears to be an English language equivalent toEP0149578 cited herein.*
	4.	5041448		1991-08-20	Janssens	
	5.	5051517		1991-09-24	Findelsen	*This patent appears to be an English language equivalent toEP0399285 cited herein.*
	6.	5223499	A	1993-06-29	Greenlee	
	7.	5234897	A	1993-08-10	Findelsen et al.	
	8.	5258380	A	1993-11-02	Janssens	
	9.	5266555	A	1993-11-30	Findelsen et al.	*This patent appears to be an English language equivalent toEP0524482 cited herein.*
	10.	5389642	A	1995-02-14	Dorsch	
	11.	5470579	A	1995-11-28	Bonte et al.	*This patent appears to be an English language equivalent toWO9107945 cited herein.*
	12.	5719279	A	1998-02-17	Kuefner-Muhl et al.	*This patent appears to be an English language equivalent toWO94/03456 cited herein.*
	13.	5753635	A	1998-05-19	Buckman	
	14.	6303661	B1	2001-10-16	Demuth	
	15.	6342601	B1	2002-01-29	Bantick	
	16.	6548481	B1	2003-04-15	Demuth et al.	
	17.	6579868	B1	2003-06-17	Osamu Asano	
	18.	6784195		2004-08-03	Hale et al.	
	19.	6821978	B2	2004-11-23	Chackalamannil	
	20.	6869947	B2	2005-03-22	Kanstrup	
	21.	7060722	B2	2006-06-13	Kitajima	
	22.	7074794	B2	2006-07-11	Kitajima	*This patent appears to be an English language equivalent toWO2002/14271 cited herein.*
	23.	7074798	B2	2006-07-11	Yoshikawa	
	24.	7074923	B2	2006-07-11	Dahanukar	
	25.	7109192	B2	2006-09-19	Hauel	
	26.	7179809	B2	2007-02-20	Eckhardt	
	27.	7183280	B2	2007-02-27	Himmelsbach	
	28.	7192952	B2	2007-03-20	Kanstrup	
	29.	7217711	B2	2007-05-15	Eckhardt	
	30.	7235538	B2	2007-06-26	Kanstrup et al.	

Examiner: /Mark Berch/ (04/16/2008)	Date Considered:

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

INFORMATION DISCLOSURE STATEMENT BY APPLICATION (Not for submission under 37 CFR 1.99) (Use several sheets if necessary)	Application Number:	10/716,141
	Filing Date:	November 18, 2003
	First Named Inventor:	Matthias ECKHARDT, et al.
	Art Unit:	1624
	Examiner Name:	Mark L. Berch
Comparable to PTO/SB/08a (05-07)	Attorney Docket Number:	01/1419

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No.	Publication Number	Kind Code	Publication Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
	1.	2007/0255900	A1	2007-09-24	Sieger	
	2.	Ser. No. 11/744701		Unpublished, filed May 4, 2007	Kohlrausch	
	3.	2002/0161001	A1	2002-10-31	Kanstrup	
	4.	2002/0169174	A1	2002-11-14	Chackalamannil et al.	
	5.	2003/0199528	A1	2003-10-23	Kanstrup	
	6.	2003/0232987	A1	2003-12-18	Dahanukar et al.	
	7.	2003/0236272	A1	2003-12-25	Carr	
	8.	2003/0105077	A1	2003-06-05	Kanstrup, A.B. et al.	
	9.	2004/0034014	A1	2004-02-19	Kanstrup, A.B. et al.	
	10.	2004/0077645	A1	2004-04-22	Himmelsbach et al.	*This document appears to be an apparent English language equivalent to WO2002068420 cited herein.*
	11.	2004/0087587	A1	2004-05-06	Himmelsbach	
	12.	2005/0020574	A1	2005-01-27	Hauel, N. et al.	
	13.	2005/0026921	A1	2005-02-03	Eckhardt	
	14.	2005/0130985	A1	2005-06-16	Himmelsbach	
	15.	2005/0171093	A1	2005-08-04	Eckhardt et al.	
	16.	2005/0187227	A1	2005-08-25	Himmelsbach et al.	
	17.	2005/0203095	A1	2005-09-15	Eckhardt	
	18.	2005/0234108	A1	2005-10-20	Himmelsbach et al.	
	19.	2005/0261352	A1	2005-11-24	Eckhardt	
	20.	2006/0004074	A1	2006-01-05	Eckhardt	
	21.	2006/0058323	A1	2006-03-16	Eckhardt et al.	
	22.	2006/0063787	A1	2006-03-23	Yoshikawa	
	23.	2006/0094722	A1	2006-05-04	Yasuda	*This document appears to be an apparent English language equivalent to Wted herein.*
	24.	2006/0142310	A1	2006-06-29	Pfrengle et al.	*This document appears to be an apparent English language equivalent to WO2006/048427 cited herein.*
	25.	2006/0173056	A1	2006-08-03	Kitajima	
	26.	2006/0205711	A1	2006-09-14	Himmelsbach	*This document appears to be an apparent English language equivalent to DE10117803 cited herein.*
	27.	2006/0247226	A1	2006-11-02	Himmelsbach	
	28.	2007/0027168	A1	2007-02-01	Pfrengle et al.	
	29.	2007/0088038	A1	2007-04-19	Eckhardt	
	30.	2007/0093659	A1	2007-04-26	Bonfanti	
	31.	2007/0142383	A1	2007-06-21	Eckhardt	
	32.	2007/0281940	A1	2007-12-06	Dugi	
	33.	2007/0219178	A1	2007-09-20	Muramoto	

Examiner: /Mark Berch/ (04/16/2008)	Date Considered:

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

INFORMATION DISCLOSURE STATEMENT BY APPLICATION (Not for submission under 37 CFR 1.99) (Use several sheets if necessary) Comparable to PTO/SB/08a (05-07)		
	Application Number:	10/716,141
	Filing Date:	November 18, 2003
	First Named Inventor:	Matthias ECKHARDT, et al.
	Art Unit:	1624
	Examiner Name:	Mark L. Berch
	Attorney Docket Number:	01/1419

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No.	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments	√[1]
	1.	2136288	CA	A1	1995-05-24	Merck Patent GmbH	*This document appears to be an apparent English language equivalent to EP0657454 cited herein*	
	2.	2418656	CA	A1	2002-02-21	Mitsubishi Pharma Corporation		
	3.	2496249	CA	A1	2004-04-03	BI Pharma GmbH & Co. KG	*This document appears to be an apparent English language equivalent to WO2004018468 cited herein*	
	4.	2496325	CA	A1	2004-03-04	BI Pharma GmbH & Co. KG	*This document appears to be an apparent English language equivalent to WO2004018468 cited herein*	
	5.	2505389	CA	A1	2004-05-21	BI Pharma GmbH & Co. KG	*This document appears to be an apparent English language equivalent to WO2004041820 cited herein*	
	6.	2508233	CA	A1	2004-06-17	BI Pharma GmbH & Co. KG	*This document appears to be an apparent English language equivalent to WO2004050658 cited herein*	
	7.	2529729	CA	A1	2004-12-23	BI International GmbH	*This document appears to be an apparent English language equivalent to WO2004111051 cited herein*	
	8.	2543074	CA	A1	2005-06-30	BI International GmbH	*This document appears to be an apparent English language equivalent to WO2005/058901 cited herein*	
	9.	2555050	CA	A1	2005-09-15	BI International GmbH	*This document appears to be an apparent English language equivalent to WO2005/085246 cited herein*	
	10.	2556064	CA	A1	2005-09-09	BI International GmbH	*This document appears to be an apparent English language equivalent to WO2005/082906 cited herein*	
	11.	2590912	CA	A1	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	*This document appears to be an English language equivalent to WO2006068163 cited herein*	
	12.	10109021	DE	A1	2002-09-05	Boehringer Ingelheim Pharma KG	*US2006/0205711 cited herein appears to be an apparent English language equivalent*	
	13.	10117803	DE	A1	2002-10-24	Boehringer Ingelheim Pharma KG		
	14.	0149578	EP	A2	1985-07-24	ADIR	*US4599338 cited herein appears to be an apparent English language equivalent*	
	15.	0399285	EP	A1	1990-11-28	Bayer AG	*US5051517 cited herein appears to be an apparent English language equivalent*	
	16.	0400974	EP	A2	1990-05-12	Merck & Co. Inc.		
	17.	0412358	EP	A1	1991-02-13	Bayer AG		√

[1] √ indicates English Language translation is attached

Examiner: /Mark Berch/ (04/16/2008)	Date Considered:

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

INFORMATION DISCLOSURE STATEMENT BY APPLICATION (Not for submission under 37 CFR 1.99) (Use several sheets if necessary)	Application Number:	10/716,141
	Filing Date:	November 18, 2003
	First Named Inventor:	Matthias ECKHARDT, et al.
	Art Unit:	1624
	Examiner Name:	Mark L. Berch
Comparable to PTO/SB/08a (05-07)	Attorney Docket Number:	01/1419

FOREIGN PATENT DOCUMENTS								
	18.	0524482	EP	A1	1993-01-27	Bayer AG	*US5266555 cited herein appears to be an apparent English language equivalent*	
	19.	0657454	EP	A1	1995-06-14	Merck Patent GmbH	*CA2136288 cited herein appears to be an apparent English language equivalent*	
	20.	1054012	EP	A1	2000-11-22	Eisai Co. Ltd		
	21.	1338595	EP	A2	2003-08-27	Eisai Co. Ltd		
	22.	1514552	EP	A1	2005-03-16	Eisai Co. Ltd		
	23.	1537880	EP	A1	2005-08-06	Takeda Pharmaceutical Company Limited		
	24.	385302	ES	A1	1973-04-16	Laboratorios Miquel		√
	25.	2707641	FR	A1	1995-01-20	Fournier Ind. Et Sante		
	26.	2003/300977	JP		2003-10-21	Sumitomo Pharma Co. Ltd		√
	27.	2006/045156	JP		2006-02-16	Sumitomo Pharma		√
	28.	S37-4895	JP		1962-06-16	Yoshitomi Pharmaceutical Corp.		√
	29.	91/07945	WO	A1	1991-06-13	LVMH Recherche	*US5470579 cited herein appears to be an apparent English language equivalent*	
	30.	94/03456	WO	A1	1994-02-17	Boehringer Ingelheim Int'l GmbH	*US5719279 cited herein appears to be an apparent English language equivalent*	
	31.	99/29695	WO	A1	6/17/1999	Astra Aktiebolag		
	32.	2002/14271	WO	A1	2002-02-21	Welfide Corporation	*US7074794 cited herein appears to be an apparent English language equivalent*	
	33.	2003/024965	WO	A2	2003-03-27	Novo Nordisk A/S		
	34.	2003/057200	WO	A2	2003-07-17	Novo Nordisk A/S		
	35.	2004/018467	WO	A2	2004-03-04	Boehringer Ingelheim Pharma GmbH & Co. KG	*CA2496325 cited herein appears to be an apparent English language equivalent*	
	36.	2004/018468	WO	A2	2004-03-04	Boehringer Ingelheim Pharma GmbH & Co. KG	*CA2496249 cited herein appears to be an apparent English language equivalent*	
	37.	2004/028524	WO	A1	2004-04-09	Eisai Co., Ltd.	*US2006/0094722 cited herein appears to be an apparent English language equivalent*	
	38.	2004/033455	WO	A2	2004-04-22	Novo Nordisk		
	39.	2004/041820	WO	A1	2004-05-21	Boehringer Ingelheim Pharma GmbH	*CA2505389 cited herein appears to be an apparent English language equivalent*	
	40.	2004/048379	WO	A1	2004-06-10	Sumitomo Pharm Co., Ltd.		√
	41.	2004/050658	WO	A1	2005-06-17	Boehringer Ingelheim Pharma GmbH & Co. KG	*CA2508233 cited herein appears to be an apparent English language equivalent*	
	42.	2004/096806	WO	A1	2004-11-11	Sumitom Pharm. Co. Ltd		√
	43.	2004/108730	WO	A1	2004-12-16	Fujisawa Pharma. Co., Ltd.		

Examiner:	/Mark Berch/ (04/16/2008)	Date Considered:	

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

INFORMATION DISCLOSURE STATEMENT BY APPLICATION (Not for submission under 37 CFR 1.99) (Use several sheets if necessary) Comparable to PTO/SB/08a (05-07)		
	Application Number:	10/716,141
	Filing Date:	November 18, 2003
	First Named Inventor:	Matthias ECKHARDT, et al.
	Art Unit:	1624
	Examiner Name:	Mark L. Berch
	Attorney Docket Number:	01/1419

FOREIGN PATENT DOCUMENTS								
	44.	2004/111051	WO	A1	2005-12-23	BI Int'l GmbH	*CA2529729 cited herein appears to be an apparent English language equivalent*	
	45.	2005/058901	WO	A1	2005-06-30	BI Int'l GmbH	*CA2543074 cited herein appears to be an apparent English language equivalent*	
	46.	2005/082906	WO	A1	2005-09-09	BI Int'l GmbH	*CA2556064 cited herein appears to be an apparent English language equivalent*	
	47.	2005/085246	WO	A1	2005-09-15	BI Int'l GmbH	*CA2555050 cited herein appears to be an apparent English language equivalent*	
	48.	2006/048427	WO	A1	2006-05-11	BI Int'l GmbH	*US2006142310 cited herein appears to be an apparent English language equivalent*	
	49.	2006/068163	WO	A1	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	*CA2590912 cited herein appears to be an English language equivalent*	
	50.	2007/017423	WO	A2	2007-02-15	F. Hoffmann-La Roche AG		

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initial*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages (s), volume-issue number(s), publisher, city and/or country where published.	√[2]
	1.	AUGUSTYNS, K. et al., The Unique Properties of Dipeptidyl-peptidase IV (DPP IV/CD 26) and the Therapeutic Potential of DPP-IV Inhibitors, Current Medicinal Chemistry, Vol. 6, No. 4, 1999, pp. 311-327.	
	2.	BELJEAN-LEYMARIE et al., Hydrazines et hydrazones hétérocycliques. IV. Synthèses de dérivés de l'hydrazine dans la série des imidazol(4,5-d)pyridazinones-4, Can. J. Chem., Vol. 61, No. 11, 1983, pp. 2563-2566.	√
	3.	BOLLAG, R.J. ET AL; "Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors," Endocrinology, Vol. 141, No. 3, 2000, pp. 1228-1235.	
	4.	BRITTAIN, H.G., "Methods for the Characterization of Polymorphs: X-Ray Powder Diffraction," Polymorphism in Pharmaceutical Solids, 1999, p. 235-238	
	5.	BUSSO ET AL., "Circulating CD26 is Negatively Associated with Inflammation in Human and Experimental Arthritis," Am. J. Path., Vol. 166, No. 2, Feb. 2005, pp. 433-442.	
	6.	CAIRA, M.R., "Crystalline polymorphism of organic compounds" Topics in Current Chemistry, Springer, Berlin, Vol. 198, 1998, p. 163-208	
	7.	CONARELLO, S.L. ET AL; "Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance," PNAS 2003; 100:6825-6830; originally published online May 14, 2003; information current as of December 2006. www.pnas.org/cgi/content/full/100/11/6825.	
	8.	DEACON, C.F. ET AL; "Dipeptidyl peptidase IV inhabitation as an approach to the treatment and prevention of type 2 diabetes: a historical perspective;" Biochemical and Biophysical Research Communications (BBRC) 294 (2002) 1-4.	
	9.	DeMEESTER, I. ET AL.; "CD26, let it cut or cut it down", Review: Immunology Today; August 1999, Vol. 20, No. 8 pp.367-375	
	10.	KOROM, S. ET AL; "Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients"[2], Transplantation, May 27, 1997, Vol. 63, no 10, pp 1495-1500.	
	11.	POSPISILIK, ET AL; "Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β -Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats; Diabetes, Vol. 52, March 2003 pp 741-750.	
	12.	RHEE ET AL.; "Nitrogen-15-Labeled Deoxynucleosides. 3. Synthesis of [3-^{15}N]-2'-Deoxyadenosine" J. Am. Chem. Soc. 1990, 112, 8174-8175	
	13.	SEDO, A. ET AL; "Dipeptidyl peptidase IV activity and/or structure homologs: Contributing factors in the pathogenesis of rheumatoid arthritis?" Arthritis Research & Therapy 2005, Vol. 7, pp. 253-269	

[2] √ indicates English Language translation is attached

Examiner: /Mark Berch/ (04/16/2008)	Date Considered:

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

INFORMATION DISCLOSURE STATEMENT BY APPLICATION (Not for submission under 37 CFR 1.99) (Use several sheets if necessary) Comparable to PTO/SB/08a (05-07)		
	Application Number:	10/716,141
	Filing Date:	November 18, 2003
	First Named Inventor:	Matthias ECKHARDT, et al.
	Art Unit:	1624
	Examiner Name:	Mark L. Berch
	Attorney Docket Number:	01/1419

	14.	TANAKA, S.. ET AL.: "Suppression of Arthritis by the Inhibitors of Dipeptidyl Peptidase IV," In. J. Immunopharmac., Vol. 19, No. 1, pp. 15-24, 1997	
	15.	WOLFF, M.E.: "Burger's Medicinal Chemistry and Drug Discovery" Fifth Edition, Vol 1: Principles and Practice, pgs. 975-977, 1994, John Wiley & Sons, Inc.,	
	16.	ZHONG, QING ET AL; "Glucose-dependent insulinotropic peptide stimulates proliferation and TGF-β release from MG-63 cells," Peptides 24 (2003) 611-616	
	17.	Chemical Abstracts Accession No. 1987:95577: Abstract of ROMANENKO et al., "Synthesis and biological activity of 3-methyl, 7- or 8-alkyl, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Farmatsevtichnii Zhurnal, 1986, (Kiev), Vol. 5, 1986, pp. 41-44.	
	18.	Chemical Abstracts Accession No. 106:95577 ROMANENKO ET AL., "Synthesis and biological activity of 3-methyl, 7-or 8-alkyl-7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Zaporozh. Med. Institute (1986)	
	19.	YOSHIKAWA, SEIJI ET AL.: Chemical Abstract of Japanese Patent No. WO 2003/104229 "Preparation of purinone derivatives as dipeptidylpeptidase IV (DPP-IV) inhibitors 2003	
	20.	PATANI GEORGE A. ET AL.: "Bioisoterism : A Rational Approach in Drug Design", Chemical Reviews, 1996, Vol. 96, No. 8, pgs. 3147-3176	
	21.	International Search Report for PCT/EP03/09127 mailed November 28, 2003.	
	22.	International Search Report for PCT/EP03/13648 mailed April 5, 2004.	
	23.	International Search Report for PCT/EP2007/054270 mailed August 14, 2007.	
	24.	International Search Report for PCT/EP2007/058181 mailed November 28, 2007.	
	25.	International Search Report for PCT/EP2007/054204 mailed August 3, 2007.	
	26.	International Search Report for PCT/EP2007/054201 mailed August 29, 2007	

Examiner: /Mark Berch/ (04/16/2008)	Date Considered:

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/